Proof-of-concept study of XOMA-213 in patients with hyperprolactinemia

Trial Profile

Proof-of-concept study of XOMA-213 in patients with hyperprolactinemia

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs XOMA-213 (Primary)
  • Indications Hyperprolactinaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors XOMA
  • Most Recent Events

    • 14 Mar 2016 New trial record
    • 09 Mar 2016 According to Xoma Corporation media release, company anticipates initiating this study by mid of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top